By Ted Bosworth
Denver—To manage the immune-related adverse events (AEs) of checkpoint inhibitors—particularly those caused by corticosteroids—treatment centers should develop policies on appropriate dosing and tapering.
“Less than 3% of patients on a checkpoint inhibitor develop significant immune-related toxicities, but these can be life-threatening,” reported Angela Duenn, PharmD, and her colleagues from the Department of Pharmacy Services at Karmanos Cancer